Alzheimer’s disease

Functional MRI: Applications in Clinical Neurology and Psychiatry

Volumn , Issue , 2006, Pages 25-34

  Gazzaley, Adam ^a   Small, Scott A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 55849122049     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (70)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82: 239-59.
2. Jack CR Jr, Petersen RC, O’Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer’s disease. Neurology 1992; 42: 183-8.
3. Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology 1997; 49: 786-94.
4. Jack CR Jr, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000; 55: 484-89.
5. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease. Neurobiol Aging 2001; 22: 747-54.
6. Mungas D, Reed BR, Jagust WJ, et al. Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. Neurology 2002; 59: 867-73.
7. de Leon MJ, Golomb J, George AE, et al. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol 1993; 14: 897-906.
8. Petersen RC, Jack CR Jr, Xu YC, et al. Memory and MRI-based hippocampal volumes in aging and AD. Neurology 2000; 54: 581-7.
9. de Toledo-Morrell L, Dickerson B, Sullivan MP, et al. Hemispheric differences in hippocampal volume predict verbal and spatial memory performance in patients with Alzheimer’s disease. Hippocampus 2000; 10: 136-42.
10. Kantarci K, Jack CR Jr, Xu YC, et al. Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology 2001; 219: 101-7.
11. Kantarci K, Petersen RC, Boeve BF, et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2005; 64: 902-4.
12. Friedland RP, Budinger TF, Ganz E, et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr 1983; 7: 590-8.
13. Benson DF, Kuhl DE, Hawkins RA, et al. The fluorodeoxyglucose 18F scan in Alzheimer’s disease and multi-infarct dementia. Arch Neurol 1983; 40: 711-4.
14. Jagust WJ, Budinger TF, Reed BR. The diagnosis of dementia with single photon emission computed tomography. Arch Neurol 1987; 44: 258-62.
15. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997; 42: 85-94.
16. Johnson KA, Jones K, Holman BL, et al. Preclinical prediction of Alzheimer’s disease using SPECT. Neurology 1998; 50: 1563-71.
17. Eberling JL, Jagust WJ, Reed BR, Baker MG. Reduced temporal lobe blood flow in Alzheimer’s disease. Neurobiol Aging 1992; 13: 483-91.
18. Chetelat G, Desgranges B, de la Sayette V, et al. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 2003; 60: 1374-7.
19. Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. NeuroReport 2001; 12: 851-5.
20. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001; 98: 10966-71.
21. Small SA, Perera GM, DeLaPaz R, et al. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer’s disease. Ann Neurol 1999; 45: 466-72.
22. Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 1990; 87: 9868-72.
23. Braak H, Braak E. Evolution of the neuropathology of Alzheimer’s disease. Acta Neurol Scand Suppl 1996; 165: 3-12.
24. Price JL, Morris JC. Tangles and plaques in nondemented aging and ‘preclinical’ Alzheimer’s disease. Ann Neurol 1999; 45: 358-68.
25. Jacobs DM, Sano M, Dooneief G, et al. Neuropsychological detection and characterization of preclinical Alzheimer’s disease. Neurology 1995; 45: 957-62.
26. Masur DM, Sliwinski M, Lipton RB, et al. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology 1994; 44: 1427-32.
27. Grober E, Kawas C. Learning and retention in preclinical and early Alzheimer’s disease. Psychol Aging 1997; 12: 183-8.
28. Small SA. Age-related memory decline current concepts and future directions. Arch Neurol 2001; 58: 360-4.
29. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993; 261: 921-3.
30. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele e4 with lateonset familial and sporadic Alzheimer’s disease. Neurology 1993; 43: 1467-72.
31. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology 1991; 41: 1006-9.
32. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-8.
33. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-92.
34. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58: 397-405.
35. Leniger-Follert E, Hossmann KA. Simultaneous measurements of microflow and evoked potentials in the somatomotor cortex of the cat brain during specific sensory activation. Pflugers Arch 1979; 380: 85-9.
36. Malonek D, Grinvald A. Interactions between electrical activity and cortical microcirculation revealed by imaging spectroscopy: implications for functional brain mapping. Science 1996; 272: 551-554.
37. Thulborn KR, Waterton JC, Matthews PM, Radda GK. Oxygenation dependence of the transverse relaxation time of water protons in whole blood at high field. Biochim Biophys Acta 1982; 714: 265-70.
38. Turner R, Le Bihan D, Moonen CT, et al. Echoplanar time course MRI of cat brain oxygenation changes. Magn Reson Med 1991; 22: 159-66.
39. Ogawa S, Tank DW, Menon R, et al. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping using MRI. Proc Natl Acad Sci USA 1992; 89: 5951-5.
40. Sperling RA, Bates JF, Chua EF, et al. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2003; 74: 44-50.
41. Machulda MM, Ward HA, Borowski B, et al. Comparison of memory fMRI response among normal, MCI, and Alzheimer’s patients. Neurology 2003; 61: 500-6.
42. Kato T, Knopman D, Liu H. Dissociation of regional activation in mild AD during visual encoding: a functional MRI study. Neurology 2001; 57: 812-16.
43. Rombouts SA, Barkhof F, Veltman DJ, et al. Functional MR imaging in Alzheimer’s disease during memory encoding. AJNR Am J Neuroradiol 2000; 21: 1869-75.
44. Dickerson BC, Salat DH, Bates JF, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 2004; 56: 27-35.
45. Cabeza R, Anderson ND, Locantore JK, McIntosh AR. Aging gracefully: compensatory brain activity in high-performing older adults. NeuroImage 2002; 17: 1394-402.
46. Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med 2000; 343: 450-6.
47. Burggren AC, Small GW, Sabb FW, Bookheimer SY. Specificity of brain activation patterns in people at genetic risk for Alzheimer disease. Am J Geriatr Psychiatry 2002; 10: 44-51.
48. Bondi MW, Houston WS, Eyler LT, Brown GG. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology 2005; 64: 501-8.
49. Smith CD, Andersen AH, Kryscio RJ, et al. Women at risk for AD show increased parietal activation during a fluency task. Neurology 2002; 58: 1197-202.
50. Raichle ME, MacLeod AM, Snyder AZ, et al. A default mode of brain function. Proc Natl Acad Sci USA 2001; 98: 676-82.
51. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer’s disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 2004; 101: 4637-42.
52. Lustig C, Snyder AZ, Bhakta M, et al. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci USA 2003; 100: 14504-9.
53. Lorente de No R. Studies on the structure of the cerebral cortex II. Continuation of the study of the ammonic system. J Psychol Neurol 1934; 46: 113-17.
54. Amaral DG, Witter MP. The three-dimensional organization of the hippocampal formation: a review of anatomical data. Neuroscience 1989; 31: 571-91.
55. Small SA. Measuring correlates of brain metabolism with high-resolution MRI: a promising approach for diagnosing Alzheimer disease and mapping its course. Alzheimer Dis Assoc Disord 2003; 17: 154-61.
56. Small SA, Chawla MK, Buonocore M, et al. Imaging correlates of brain function in monkeys and rats isolates a hippocampal subregion differentially vulnerable to aging. Proc Natl Acad Sci USA 2004; 101: 7181-6.
57. Small SA, Tsai WY, DeLaPaz R, et al. Imaging hippocampal function across the human life span: Is memory decline normal or not? Ann Neurol 2002; 51: 290-5.
58. Mayeux R. Evaluation and use of diagnostic tests in Alzheimer’s disease. Neurobiol Aging 1998; 19: 139-43.
59. Small SA, Mayeux R. Delerium and dementia. In: Rowland LP (ed). Merritt’s Neurology, 10th edn. Philadelphia: Lippincott Williams & Wilkins. 2000: 3-6.
60. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19.
61. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and ß-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002; 10: 24-35.
62. Wadghiri YZ, Sigurdsson EM, Sadowski M, et al. Detection of Alzheimer’s amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 2003; 50: 293-302.
63. Higuchi M, Iwata N, Matsuba Y, et al. 19F and 1H MRI detection of amyloid ß plaques in vivo. Nature Neurosci 2005; 8: 527-33.
64. Helpern JA, Lee SP, Falangola MF, et al. MRI assessment of neuropathology in a transgenic mouse model of Alzheimer’s disease. Magn Reson Med 2004; 51: 794-8.
65. Jack CR Jr, Garwood M, Wengenack TM, et al. In vivo visualization of Alzheimer’s amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med 2004; 52: 1263-71.
66. Vanhoutte G, Dewachter I, Borghgraef P, et al. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer’s disease. Magn Reson Med 2005; 53: 607-13.
67. Rombouts SA, Van Swieten JC, Pijnenburg YA, et al. Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD. Neurology 2003; 60: 1904-8.
68. Rombouts SA, Barkhof F, Van Meel CS, Scheltens P. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2002; 73: 665-71.
69. Saykin AJ, Wishart HA, Rabin LA, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 2004; 127: 1574-83.
70. Goekoop R, Rombouts SA, Jonker C, et al. Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. NeuroImage 2004; 23: 1450-9.